Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment
Background This study aimed to explore the prognostic role of pan-immune-inflammation value (PIV) and develop a new risk model to guide individualized adjuvant systemic treatment following radiofrequency ablation (RFA) for early-stage hepatocellular carcinoma (HCC).Materials and methods Patients wit...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | International Journal of Hyperthermia |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/02656736.2024.2355279 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560887132946432 |
|---|---|
| author | Xuexia Liang Juyuan Bu Yanhui Jiang Shuqin Zhu Qing Ye Yun Deng Wuzhu Lu Qiaodan Liu |
| author_facet | Xuexia Liang Juyuan Bu Yanhui Jiang Shuqin Zhu Qing Ye Yun Deng Wuzhu Lu Qiaodan Liu |
| author_sort | Xuexia Liang |
| collection | DOAJ |
| description | Background This study aimed to explore the prognostic role of pan-immune-inflammation value (PIV) and develop a new risk model to guide individualized adjuvant systemic treatment following radiofrequency ablation (RFA) for early-stage hepatocellular carcinoma (HCC).Materials and methods Patients with early-stage HCC treated by RFA were randomly divided into training cohort A (n = 65) and testing cohort B (n = 68). Another 265 counterparts were enrolled into external validating cohort C. Various immune-inflammatory biomarkers (IIBs) were screened in cohort A. Prognostic role of PIV was evaluated and validated in cohort B and C, respectively. A nomogram risk model was built in cohort C and validated in pooled cohort D. Clinical benefits of adjuvant anti-angiogenesis therapy plus immune checkpoint inhibitor (AA-ICI) following RFA was assessed in low- and high-risk groups.Results The cutoff point of PIV was 120. High PIV was an independent predictor of unfavorable recurrence-free survival (RFS) and overall survival (OS). RFS and OS rates of patients with high PIV were significantly lower than those with low PIV both in cohort B (PRFS=0.016, POS=0.011) and C (PRFS<0.001, POS<0.001). The nomogram model based on PIV, tumor number and BCLC staging performed well in risk stratification in external validating cohort C. Adjuvant AA-ICI treatment showed an added benefit in OS (p = 0.011) for high-risk patients.Conclusions PIV is a feasible independent prognostic factor for RFS and OS in early-stage HCC patients who received curative RFA. The proposed PIV-based nomogram risk model could help clinicians identify high-risk patients and tailor adjuvant systemic treatment and disease follow-up scheme. |
| format | Article |
| id | doaj-art-438517ed4fbd4036944a70366dce8c4f |
| institution | Kabale University |
| issn | 0265-6736 1464-5157 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Hyperthermia |
| spelling | doaj-art-438517ed4fbd4036944a70366dce8c4f2025-01-03T09:30:27ZengTaylor & Francis GroupInternational Journal of Hyperthermia0265-67361464-51572024-12-0141110.1080/02656736.2024.2355279Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatmentXuexia Liang0Juyuan Bu1Yanhui Jiang2Shuqin Zhu3Qing Ye4Yun Deng5Wuzhu Lu6Qiaodan Liu7Cancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaDepartment of Gastrointestinal Surgery, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaCancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaDepartment of Pathology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaDepartment of Ultrasound, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaCancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaGuangdong-Hong Kong-Macao University Joint Laboratory of Interventional Medicine, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaCancer Center, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, ChinaBackground This study aimed to explore the prognostic role of pan-immune-inflammation value (PIV) and develop a new risk model to guide individualized adjuvant systemic treatment following radiofrequency ablation (RFA) for early-stage hepatocellular carcinoma (HCC).Materials and methods Patients with early-stage HCC treated by RFA were randomly divided into training cohort A (n = 65) and testing cohort B (n = 68). Another 265 counterparts were enrolled into external validating cohort C. Various immune-inflammatory biomarkers (IIBs) were screened in cohort A. Prognostic role of PIV was evaluated and validated in cohort B and C, respectively. A nomogram risk model was built in cohort C and validated in pooled cohort D. Clinical benefits of adjuvant anti-angiogenesis therapy plus immune checkpoint inhibitor (AA-ICI) following RFA was assessed in low- and high-risk groups.Results The cutoff point of PIV was 120. High PIV was an independent predictor of unfavorable recurrence-free survival (RFS) and overall survival (OS). RFS and OS rates of patients with high PIV were significantly lower than those with low PIV both in cohort B (PRFS=0.016, POS=0.011) and C (PRFS<0.001, POS<0.001). The nomogram model based on PIV, tumor number and BCLC staging performed well in risk stratification in external validating cohort C. Adjuvant AA-ICI treatment showed an added benefit in OS (p = 0.011) for high-risk patients.Conclusions PIV is a feasible independent prognostic factor for RFS and OS in early-stage HCC patients who received curative RFA. The proposed PIV-based nomogram risk model could help clinicians identify high-risk patients and tailor adjuvant systemic treatment and disease follow-up scheme.https://www.tandfonline.com/doi/10.1080/02656736.2024.2355279Hepatocellular carcinomaradiofrequency ablationpan-immune-inflammation valueprognosis predictoradjuvant systemic treatment |
| spellingShingle | Xuexia Liang Juyuan Bu Yanhui Jiang Shuqin Zhu Qing Ye Yun Deng Wuzhu Lu Qiaodan Liu Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment International Journal of Hyperthermia Hepatocellular carcinoma radiofrequency ablation pan-immune-inflammation value prognosis predictor adjuvant systemic treatment |
| title | Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment |
| title_full | Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment |
| title_fullStr | Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment |
| title_full_unstemmed | Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment |
| title_short | Prognostic significance of pan-immune-inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation: potential role for individualized adjuvant systemic treatment |
| title_sort | prognostic significance of pan immune inflammation value in hepatocellular carcinoma treated by curative radiofrequency ablation potential role for individualized adjuvant systemic treatment |
| topic | Hepatocellular carcinoma radiofrequency ablation pan-immune-inflammation value prognosis predictor adjuvant systemic treatment |
| url | https://www.tandfonline.com/doi/10.1080/02656736.2024.2355279 |
| work_keys_str_mv | AT xuexialiang prognosticsignificanceofpanimmuneinflammationvalueinhepatocellularcarcinomatreatedbycurativeradiofrequencyablationpotentialroleforindividualizedadjuvantsystemictreatment AT juyuanbu prognosticsignificanceofpanimmuneinflammationvalueinhepatocellularcarcinomatreatedbycurativeradiofrequencyablationpotentialroleforindividualizedadjuvantsystemictreatment AT yanhuijiang prognosticsignificanceofpanimmuneinflammationvalueinhepatocellularcarcinomatreatedbycurativeradiofrequencyablationpotentialroleforindividualizedadjuvantsystemictreatment AT shuqinzhu prognosticsignificanceofpanimmuneinflammationvalueinhepatocellularcarcinomatreatedbycurativeradiofrequencyablationpotentialroleforindividualizedadjuvantsystemictreatment AT qingye prognosticsignificanceofpanimmuneinflammationvalueinhepatocellularcarcinomatreatedbycurativeradiofrequencyablationpotentialroleforindividualizedadjuvantsystemictreatment AT yundeng prognosticsignificanceofpanimmuneinflammationvalueinhepatocellularcarcinomatreatedbycurativeradiofrequencyablationpotentialroleforindividualizedadjuvantsystemictreatment AT wuzhulu prognosticsignificanceofpanimmuneinflammationvalueinhepatocellularcarcinomatreatedbycurativeradiofrequencyablationpotentialroleforindividualizedadjuvantsystemictreatment AT qiaodanliu prognosticsignificanceofpanimmuneinflammationvalueinhepatocellularcarcinomatreatedbycurativeradiofrequencyablationpotentialroleforindividualizedadjuvantsystemictreatment |